ABBOTT LABORATORIES
NYSE: ABT·Abbott Park, Illinois·CIK 0000001800
- Price
- $107.45
- Base IV
- $79.70
Valuation snapshot
At $107.45, the price sits between our base case ($79.70) and bull case ($137.08).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $79.70
- 74% of the price · range $34.73–$137.08
- Price vs base case
- 35% above
- $107.45 against $79.70
- Base case · our researched forecast, 2026-11-05See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 7.0% since this valuation was struck on 2026-11-05, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $34.73 to bull $137.08. Values per share.
Price against each value
- Bear case
- $34.73
- Price 209% above
- No growth
- …
- —
- Base case
- $79.70
- Price 35% above
What does Abbott Laboratories do?
Abbott makes glucose monitors, heart devices, lab and rapid tests, infant and adult nutrition formulas, and generic medicines so people can track diabetes, treat heart disease, get diagnosed, and stay nourished.
It brought in $48.2B of sales in the 12 months to Sep 2026.
Led by Robert B. Ford, Chairman of the Board and Chief Executive Officer since 2021. Form 10-K for Abbott Laboratories filed 02/20/2026 (FY2025), executive officers
- Industry
- Healthcare
- Based in
- Abbott Park, Illinois
- Trades on
- NYSE as ABT
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 10¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 43¢ of every dollar.
- Making what it sells43¢
- Research and development7¢
- Sales, marketing and admin31¢
- Everything else it takes to operate5¢
- Tax4¢
- Left as profit10¢
Who pays Abbott Laboratories, and for what?
Abbott makes and sells health care products in more than 100 countries. Its four businesses sell medical devices such as glucose sensors and heart devices, lab and cancer tests, nutrition products such as infant formula and Ensure, and lower-cost branded generic medicines sold mostly outside the U.S. In 2025, about 61% of its sales came from outside the U.S.
Abbott is paid by hospitals, labs, doctors' offices, pharmacies, wholesalers, retailers, government agencies and individual consumers, and it says losing any single customer would not have a major effect.
Medical Devices
48%Glucose sensors for people with diabetes (FreeStyle Libre), and devices that treat heart rhythm problems, heart failure, blood vessel and heart valve conditions, and chronic pain.
FreeStyle Libre 3 Plus glucose sensor and packaging.Image: Abbott Diagnostic Products
20%Machines and tests used by hospital and commercial labs, rapid tests and point-of-care tests. Cancer screening tests such as Cologuard were added in March 2026, after the Exact Sciences purchase.
BinaxNOW COVID-19 Antigen Self Test kit.G. Edward Johnson, CC BY 4.0, via Wikimedia Commons Nutritional Products
19%Infant formula and children's nutrition (such as Similac), adult nutrition drinks (such as Ensure and Glucerna), and feeding products for patients.
Similac 360 Total Care infant formula.Image: Target Established Pharmaceutical Products
13%Branded generic medicines for stomach, women's health, heart, pain, nervous system and breathing conditions. They are sold mainly in emerging markets outside the U.S.
Duphaston 10 mg tablets.Image: Abbott
Where its work physically happens, beyond headquarters:
- Kilkenny FreeStyle Libre Plant — Kilkenny, Ireland. This 323,000-square-foot facility has Abbott's highest production capacity for FreeStyle Libre sensors, supporting a CGM franchise that generated $7.6 billion of sales in 2025.
- Sturgis Infant Formula Plant — Sturgis, United States. The 788,000-square-foot plant produces infant formula at sufficient volume that its 2022 shutdown contributed to a nationwide shortage, making it a critical Nutrition supply asset and operational-risk concentration.
- Clonmel Vascular Facility — Clonmel, Ireland. This combined manufacturing and R&D center produces XIENCE drug-eluting stent technology and develops next-generation vascular and endovascular products for Abbott's fast-growing Medical Devices segment.
- Singapore Nutrition Plant — Singapore, Singapore. The 500,000-square-foot plant is described by Abbott as one of its most significant global facilities and supplies science-based nutrition products across Asia-Pacific.
- Longford Diagnostics Plant — Longford, Ireland. This diagnostics manufacturing site supports Abbott's core-laboratory business, whose 2025 growth was driven by continued expansion of Alinity sales outside China.
How is the business doing?
Sales grew from $34.6B in 2020 to $44.3B in 2025, about 5% a year.
Running the business leaves about 14¢ of each sales dollar as operating profit, about the same as 15¢ in 2020.
After paying for its upkeep and new investment, it had $6.8B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Abbott says it exists to help people live healthier lives through its health care products.
“help people live their healthiest possible lives”
Who is responsible for the plan?
Robert B. FordChairman of the Board and Chief Executive OfficerLeads Abbott as CEO and chairs its Board of Directors. The CEO oversees all of Abbott's reporting segments, which sell medical devices, diagnostics, nutrition products and established pharmaceuticals.
- Lisa D. EarnhardtExecutive Vice President and Group President, Medical Devices
Oversees Abbott's Medical Devices businesses, including Diabetes Care and its continuous glucose monitoring (CGM) products. The Medical Devices segment earns revenue from device sales, and the FY2025 10-K reports $7.6 billion of CGM sales in 2025.
Roles checked November 6, 2026.
What management says it is working on now:
Faster growth in the second half of 2026
The CEO said the second-quarter results show building momentum, and he expects sales and earnings growth to speed up in the second half of 2026.
Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS GuidanceBringing Exact Sciences into Abbott
Abbott completed its purchase of cancer-test maker Exact Sciences in March 2026 for about $20.6 billion. The deal moves Abbott into cancer screening and testing, and Exact Sciences added about $1.0 billion of sales in the first half of 2026.
Abbott Laboratories Form 10-Q for quarter ended June 30, 2026Growing its heart rhythm devices
Management said the business that treats irregular heartbeats has started to speed up. It is rolling out its newer Volt catheter, which treats irregular heartbeats using electrical pulses, and new TactiFlex catheters.
Abbott's Q2 2026 earnings call: What drove results and what should investors watch next?Expanding glucose sensors
Sales of its glucose sensors topped $2 billion in the quarter. Abbott is adding new products such as Libre Duo, a sensor that tracks both glucose and ketones.
Abbott's Q2 2026 earnings call: What drove results and what should investors watch next?Steadying the nutrition business
Nutrition sales fell 3.1% in the second quarter of 2026. Management pointed to Abbott regaining the lead in U.S. infant formula as a sign the business is stabilising.
Abbott's Q2 2026 earnings call: What drove results and what should investors watch next?
- Comparable sales growth, full year 2026
- 6.5% to 7.5%
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- Adjusted earnings per share, full year 2026
- $5.45 to $5.60
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
What's changing right now?
Growth is picking up. In Q3 2026 it sold 14% more than a year earlier. The year before, quarters averaged 8%.
Its operating margin is narrower than a year ago: 10¢ per sales dollar, against 18¢.
Since Sep 2026 the share price has fallen 1%, from $108.79 to $107.45.
Recently
October 21, 2026
Cancer Diagnostics (Exact Sciences) sales, quarterly changed to $968.0M
Abbott Q3 2026 results releaseJanuary 22, 2026
Reported net sales growth, full year changed to 5.7%
Abbott Q4/FY2025 results (8-K Ex. 99.1)December 31, 2025
Diabetes Care annual sales changed to $8.0B
Abbott 2025 Form 10-K sales table
Coming up
Q3 2026
Volt heart catheter goes to full release
Abbott launched its newer Volt catheter in the U.S. in May 2026 to a limited set of users. It expected to make it widely available in the third quarter.
Abbott's Q2 2026 earnings call: What drove results and what should investors watch next?Within 12 months of July 2026
Libre Duo U.S. launch
Libre Duo, a sensor that tracks both glucose and ketones, won European approval in May 2026. Management said it planned to bring the product to the U.S. once the FDA cleared it.
Abbott's Q2 2026 earnings call: What drove results and what should investors watch next?Within 12 months of July 2026
Amulet 360 FDA decision
In May 2026, Abbott asked the FDA to approve Amulet 360, a heart implant that lowers stroke risk. It hopes to launch it in the U.S. within a year.
Abbott's Q2 2026 earnings call: What drove results and what should investors watch next?Within 12 months of July 2026
More U.S. heart device launches
Management expects to launch a device that breaks up hard deposits in heart arteries and the TactiFlex Duo catheter, which treats irregular heartbeats, in the U.S. over the next 12 months.
Abbott's Q2 2026 earnings call: What drove results and what should investors watch next?
Our own estimate moved too: the base case went from $55.46 to $79.70 a share between our last two valuations. The biggest reason: R&D expense as percent of revenue moved from an unreported prior value to 6.7%, as reported in Abbott Laboratories 2025 Form 10-K Income Statement.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Much more debt after the Exact Sciences purchase
Abbott borrowed $20 billion to buy Exact Sciences, so its long-term debt went from about $9.9 billion to about $29.6 billion. The company says this could leave it less room to act, and the purchase may not deliver what it expected.
From the company's own filingsWould hit how much it has to reinvestAbbott Laboratories Form 10-Q for quarter ended June 30, 2026
Infant formula lawsuits
About 1,760 lawsuits say Abbott's formula for premature babies caused a serious bowel illness. One jury awarded a plaintiff $495 million in 2024, and Abbott has appealed.
From the company's own filingsWould hit how much of each sale it keepsAbbott Laboratories Form 10-K for fiscal year 2025
Competition and new technology
Rival products and new technologies, including AI, could reduce demand for Abbott's devices and tests. Glucose sensors and heart rhythm devices are especially competitive markets.
From the company's own filingsWould hit how fast sales growAbbott Laboratories Form 10-K for fiscal year 2025
Product safety, recalls and regulators
Its products need approval from regulators and must keep meeting their rules. Factory problems, safety issues or rule breaches can lead to recalls, fines or production stops, as happened with infant formula in 2022.
From the company's own filingsWould hit how fast sales growAbbott Laboratories Form 10-K for fiscal year 2025
Global exposure: tariffs, currencies and conflicts
About 61% of 2025 sales came from outside the U.S. Tariffs, sanctions, wars and exchange-rate swings can raise Abbott's costs and shrink the dollar value of its sales.
From the company's own filingsWould hit how fast sales growAbbott Laboratories Form 10-K for fiscal year 2025
Pressure on prices
Governments and insurers push to pay less for health care. China's bulk-buying programmes, for example, cut Abbott's lab test sales there in 2024 and 2025.
From the company's own filingsWould hit how much of each sale it keepsAbbott Laboratories Form 10-K for fiscal year 2025
Legacy COVID-19 testing revenues declined to $297 million in 2025 from $747 million in 2024, continuing to moderate total diagnostics turnover.
From our researchWould hit how fast sales growAbbott 2025 10-K Diagnostics Review
Major portfolio transformations such as the $21 billion acquisition of Exact Sciences require episodic bursts of external capital.
From our researchWould hit how much it has to reinvestAbbott Completes Acquisition of Exact Sciences
Is it a good business?
From 2014 to 2025 it earned between 3% and 16% on the capital invested in it, a median of 11%. Its cost of capital in the latest valuation is 7.4%; returns were above it in 9 of the 10 years.
From 2014 to 2025 it earned between 2% and 28% on its shareholders' equity, a median of 14%.
Over 10 years its operating margin ranged from 6¢ to 20¢ per sales dollar, a median of 16¢. Gross margin ran from 47¢ to 57¢.
Cost of capital 7.4%
The number of shares has held roughly steady over the past year.
It owes $27.1B more than it holds in cash, about 4.1 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $107.45. Our put its value between $34.73 and $137.08, with $79.70 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $34.73
This cautious scenario envisions that increasing competition in diabetes sensors and healthcare cost pressures reduce sales growth to low single digits while acquisition integration expenses weigh on overall profitability.
Base case, $79.70
This steady scenario assumes that rapid adoption of diabetes monitors and cancer screening tools maintains healthy mid-single-digit sales growth, allowing profit profitability to gradually recover toward historical highs.
Bull case, $137.08
This favorable scenario anticipates that breakthrough heart and diabetes devices alongside expanded cancer screening drive high single-digit sales growth while operational efficiency pushes profitability to record levels.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 35%
For Abbott Laboratories to be worth today's $107.45, sales would need to grow about 12.1% a year. We assume 6.1%. Over the last 5 years, sales grew 2.7% a year.
Or, if sales grow 6.1% as we assume, the price works with a profit margin of 26.5% (we assume 20.5%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 12.1% a year?
Try your own numbersWe're moderately sure of this range: it scores 60 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $79.70 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average6.1%
- Operating margin20.5%
- Long-term growth rate2.8%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$79.70 -25.8%


